Is Now a Good Time to Buy the Dip in Eli Lilly Stock?

Owning shares of pharmaceutical giant Eli Lilly (NYSE: LLY) has generally been a great idea over the past year. Lilly's diabetes medication Mounjaro and its sibling treatment for chronic weight management Zepbound have evolved into blockbuster drugs in short order -- helping fuel Lilly stock to new all-time highs earlier this year.However, Lilly's shares (like pharmaceutical companies in general) tend to be quite volatile. As I write this, the stock has fallen by 12% just in the month of November. With the price now down 22% from intra-year highs, is now a good time to buy the dip in Eli Lilly stock?Let's take a look at what could be influencing the ongoing sell-off. From there, the case for or against investing in Lilly should become much clearer.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool